 Connection
Michael Szarek to Ischemic Attack, Transient
This is a "connection" page, showing publications Michael Szarek has written about Ischemic Attack, Transient.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.435 |
|
|
|
-
Szarek M, Amarenco P, Callahan A, Goldstein LB, Sillesen H, Welch KM. Reply: Hemorrhagic Stroke, All-Cause Death, and Intensive LDL-C Lowering: Evidence From SPARCL and Beyond. J Am Coll Cardiol. 2020 08 18; 76(7):886-888.
Score: 0.662
-
Szarek M, Amarenco P, Callahan A, DeMicco D, Fayyad R, Goldstein LB, Laskey R, Sillesen H, Welch KM. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial. J Am Coll Cardiol. 2020 05 05; 75(17):2110-2118.
Score: 0.643
-
Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A, Hennerici M, Simunovic L, Zivin JA, Welch KM. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2007 Dec; 38(12):3198-204.
Score: 0.068
-
Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 08 10; 355(6):549-59.
Score: 0.063
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|